PSMA tracers agree on Pluvicto eligibility, diverge on tumor volume

Wednesday, December 2 | 1:30 p.m.-2:30 p.m. | W6-SSNMMI06-5 | Room S405 

Two U.S.-cleared prostate-specific membrane antigen (PSMA) PET radiotracers are clinically interchangeable for determining eligibility for lutetium-177 (Lu-177) PSMA-617 (Pluvicto) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to research in this session. 

Yalda Nikanpour, MD, of Mayo Clinic in Rochester, MN, and colleagues enrolled 96 mCRPC patients referred for Pluvicto who underwent both F-18 PSMA-DCFPyL and Ga-68 PSMA-11 PET/CT within 90 days. The researchers extracted molecular imaging PSMA (miPSMA) scores ranging from 0 to 3 per PROMISE criteria, using mediastinal blood pool, liver, and parotid glands as reference organs, with eligibility defined as a score of 2 or higher. Volumetric tumor burden metrics were extracted from each scan as well. 

Eligibility was concordant in 91 of 96 patients (94.8%), with no systematic bias between tracers. miPSMA scores were identical in 84% of patients, with a mean difference of 0.06. Among volumetric metrics, SUVmean demonstrated equivalence between tracers, while SUVmax showed no significant mean bias but wide inter-individual variability. Total tumor volume (TTV) and a second volumetric metric were systematically higher on Ga-68 PSMA-11 than F-18 PSMA-DCFPyL (by 20.2% and 24.4%), driven by tracer-dependent differences in background uptake and lesion contrast, the researchers noted. 

PSMA PET/CT is required to confirm Pluvicto eligibility, and patients may receive different tracers at different centers or across treatment cycles, the researchers noted, raising the practical question of whether tracer choice affects the eligibility call or downstream tumor burden assessments. 

“Both PSMA PET/CT tracers are clinically interchangeable for ¹⁷⁷Lu-PSMA-617 eligibility decisions; however, volumetric tumor burden metrics should not be used interchangeably across tracers,” Nikanpour and colleagues noted. 

Check out this Wednesday session to learn more. 

Page 1 of 2
Next Page